×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RHHBY – roche holding ltd s/adr (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RHHBY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/2
02:46 pm
rhhby
Target RWE Strengthens Leadership Team with Appointments Across Delivery, Finance and Commercial [Yahoo! Finance]
Low
Report
Target RWE Strengthens Leadership Team with Appointments Across Delivery, Finance and Commercial [Yahoo! Finance]
4/2
11:18 am
rhhby
Adrenocortical Carcinoma Market Report 2026: Innovative Therapies Set to Transform the $4 Billion Adrenocortical Carcinoma Landscape [Yahoo! Finance]
Low
Report
Adrenocortical Carcinoma Market Report 2026: Innovative Therapies Set to Transform the $4 Billion Adrenocortical Carcinoma Landscape [Yahoo! Finance]
3/31
10:18 pm
rhhby
Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma [TheStreet.com]
Low
Report
Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma [TheStreet.com]
3/30
09:27 am
rhhby
Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform [Yahoo! Finance]
Low
Report
Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform [Yahoo! Finance]
3/30
09:09 am
rhhby
Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratories [Yahoo! Finance]
Low
Report
Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratories [Yahoo! Finance]
3/30
09:00 am
rhhby
Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratories
Low
Report
Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratories
3/30
01:18 am
rhhby
Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply [Yahoo! Finance]
Low
Report
Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply [Yahoo! Finance]
3/30
12:52 am
rhhby
Qyuns Therapeutics-B (02509) 2025 Revenue Surges Over 4-Fold; Adjusted Profit Reaches Approximately RMB356 Million, Turning a Profit Year-on-Year [Yahoo! Finance]
Low
Report
Qyuns Therapeutics-B (02509) 2025 Revenue Surges Over 4-Fold; Adjusted Profit Reaches Approximately RMB356 Million, Turning a Profit Year-on-Year [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
UPDATE 1-European stock markets calm after pandemic-driven crash [Reuters]
13.0%
3/24 Roche says limit tests to people with coronavirus symptoms [Reuters] 5.4%
3/16 Roche begins shipments of first 400,000 COVID-19 tests to laboratories across US to begin patient testing under FDA Emergency Use Authorization 5.2%
3/4 MORNING BID-Rate cuts no panacea for virus damage [Reuters] 4.9%
3/19 Roche to test Acterma as a treatment for COVID-19 [MarketWatch] 4.7%
4/13 Researchers on the hunt for coronavirus treatments [CBS News] 3.6%
3/9 FDA OKs new use of Boehringer Ingelheim's Ofev [Seeking Alpha] 3.4%
4/22 Coffee, chocolates and pills shield Swiss stocks from virus rout [Reuters] 3.0%
2/5 Is Illumina Stock a Buy? [The Motley Fool] 2.8%
1/30 BRIEF-Roche Q4 China Sales Fell Amid Inventory Cuts, Sees 2020 Double-Digit Growth [Reuters] 2.5%
3/24 Roche says limit tests to people with coronavirus symptoms [Reuters] 5.4%
3/16 Roche begins shipments of first 400,000 COVID-19 tests to laboratories across US to begin patient testing under FDA Emergency Use Authorization 5.2%
3/4 MORNING BID-Rate cuts no panacea for virus damage [Reuters] 4.9%
3/19 Roche to test Acterma as a treatment for COVID-19 [MarketWatch] 4.7%
4/13 Researchers on the hunt for coronavirus treatments [CBS News] 3.6%
3/9 FDA OKs new use of Boehringer Ingelheim's Ofev [Seeking Alpha] 3.4%
4/22 Coffee, chocolates and pills shield Swiss stocks from virus rout [Reuters] 3.0%
2/5 Is Illumina Stock a Buy? [The Motley Fool] 2.8%
1/30 BRIEF-Roche Q4 China Sales Fell Amid Inventory Cuts, Sees 2020 Double-Digit Growth [Reuters] 2.5%
TOP News Decliners
3/12
BRIEF-Roche Gets EU Approval For Chronic Lymphocytic Leukaemia Treatment [Reuters]
-9.0%
3/13 Roche jumps after coronavirus test gets FDA approval [Yahoo! Finance News] -7.4%
3/19 Roche to test Actemra as a treatment for COVID-19 [MarketWatch] -7.4%
3/7 Belreca: An Investment Holding Trading At A Discount With The Overhead Cost Of An ETF [Seeking Alpha] -5.8%
3/11 BRIEF-Roche Receives FDA Approval For Cervical Cancer Prevention Test [Reuters] -4.3%
3/17 Coronavirus testing shouldn’t be this complicated [The Verge] -4.0%
3/23 Roche CEO says broad coronavirus testing in U.S. could take weeks - CNBC [Reuters] -3.5%
4/28 Coronavirus antibody tests have "really terrible" accuracy, researcher says [CNN] -3.3%
2/27 Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience [Forbes] -3.2%
1/24 UPDATE 1-Roche's Tecentriq fails trial in form of urothelial cancer [Reuters] -2.8%
3/13 Roche jumps after coronavirus test gets FDA approval [Yahoo! Finance News] -7.4%
3/19 Roche to test Actemra as a treatment for COVID-19 [MarketWatch] -7.4%
3/7 Belreca: An Investment Holding Trading At A Discount With The Overhead Cost Of An ETF [Seeking Alpha] -5.8%
3/11 BRIEF-Roche Receives FDA Approval For Cervical Cancer Prevention Test [Reuters] -4.3%
3/17 Coronavirus testing shouldn’t be this complicated [The Verge] -4.0%
3/23 Roche CEO says broad coronavirus testing in U.S. could take weeks - CNBC [Reuters] -3.5%
4/28 Coronavirus antibody tests have "really terrible" accuracy, researcher says [CNN] -3.3%
2/27 Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience [Forbes] -3.2%
1/24 UPDATE 1-Roche's Tecentriq fails trial in form of urothelial cancer [Reuters] -2.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: